Lipid peroxidation as a source of VOCs on breath

The collection and analysis of exhaled breath can be a rich source of information relevant to health and disease. Over 1000 different volatile organic compounds (VOCs) have been detected on breath and studies have shown that these can be related to the onset, progression and treatment of a wide range of diseases. As such, breath analysis has many potential applications in early detection and precision medicine.

VOCs on breath have many origins, both inside (endogenous) and outside (exogenous) the body. Many metabolic processes produce VOCs and these are thought to be the main source of endogenous VOCs on breath, however the evidence linking metabolic processes to exhaled VOCs is still limited [1]. One process that is often proposed as a source of exhaled VOCs in various contexts is lipid peroxidation.

What is lipid peroxidation?

Lipid peroxidation is a result of oxidative stress within cells, which can be caused by disease processes or immune responses such as inflammation [2]. In stressed cells, a relative lack of antioxidant defence leads to an increase in reactive oxygen species (ROS) which indiscriminately attack other components of the cell including DNA, proteins and lipids. Lipid peroxidation is a chemical chain reaction between ROS and unsaturated fatty acids that results in the production of VOCs [3]. There is significant interest in discovering biomarkers for oxidative stress both in its own right and as a factor in many illnesses. As such, exhaled VOCs associated with lipid peroxidation have a wide range of potential applications.

Lipid peroxidation typically produces linear or branched VOCs, with aldehydes being one of the most common products. Often these aldehydes are reduced by enzymes, resulting in alcohols, alkanes and other organic compounds [1,4]. The specific compounds produced depend on the structure of the fatty acids involved. Numerous papers in the breath research field suggest lipid peroxidation as a theoretical source for candidate biomarkers, this has been seen repeatedly in a number of major areas including respiratory diseases, liver diseases and cancer.

Linking lipid peroxidation and exhaled VOCs

VOC Biomarkers have been investigated in respiratory conditions including asthma, COPD and lung cancer. These conditions often share similar inflammatory responses of which lipid peroxidation is a known component that could contribute to elevated levels of hydrocarbon VOCs [5], particularly aldehydes [6]. In cancers, both in the lung [7,8,9] and elsewhere, accumulated oncogenic mutations and a high metabolic demand often lead to oxidative stress. In fact, pentane was one of the first breath biomarkers reported for breast cancer [10]. The connection between cancer biology and VOCs from lipid peroxidation was recently illustrated further through an in vitro study of cultured cells [11].

In a previous blog, we reviewed VOCs associated with fatty liver diseases and cirrhosis where several studies have suggested associations with lipid peroxidation [12,13]. Exhaled VOCs linked to lipid peroxidation have been seen in other conditions too including heart transplant rejection [14,15,16], mesothelioma [17], angina [18], Crohn’s disease and ulcerative colitis [19,20]. Table 1 summarizes further VOCs with proposed links to lipid peroxidation that have been identified in various disease contexts.

While lipid peroxidation appears to contribute to exhaled VOC profiles in many diseases, it’s interesting to note that the specific VOCs involved seem to vary by context. This effect may be due to the different lipid compositions and redox enzyme complements of different cell types, resulting in a more unique set of VOC products.

Towards biomarker panels for oxidative stress

Despite the richness of publications proposing lipid peroxidation as a source of exhaled VOCs, work is still needed to conclusively demonstrate the connection between biological processes and VOC emissions. We are currently undertaking a project to specifically identify the VOC products produced as a result of lipid peroxidation of various fatty acids in vitro. This is a key step towards demonstrating that specific VOCs are produced through lipid peroxidation and conclusively associating different fatty acids with distinct sets of VOC products.

To date, research demonstrating the biological origins of prospective VOC biomarkers identified through in vivo clinical studies has been limited. More recently, VOC emissions from in vitro cell lines have been used to help develop the link between cell metabolism and VOCs detected in breath and other sampling media [1,11]. Our new in vitro capabilities mean that we can support you to both discover and validate biomarkers on breath as well as performing in vitro studies to investigate the mechanistic origins of your VOCs of interest.

Get in touch to discuss how we can support your research through identification and analysis of VOCs in vivo and in vitro.

References

1. Filipiak et al. A Compendium of Volatile Organic Compounds (VOCs) Released By Human Cell Lines, Curr Med Chem. 2016, DOI: 10.2174/0929867323666160510122913
2. Zanella et al. Comparison of the effect of chemically and biologically induced inflammation on the volatile metabolite production of lung epithelial cells by GC×GC-TOFMS, Analyst. 2020, DOI: 10.1039/d0an00720j
3. Ratcliffe et al. A mechanistic study and review of volatile products from peroxidation of unsaturated fatty acids: an aid to understanding the origins of volatile organic compounds from the human body, J Breath Res. 2020, DOI: 10.1088/1752-7163/ab7f9d
4. Calenic et al. Oxidative stress and volatile organic compounds: interplay in pulmonary, cardio-vascular, digestive tract systems and cancer, Open Chem. 2015, DOI: 10.1515/chem-2015-0105
5. Van de Kant et al. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review, Respir. Res. 2012, DOI: 10.1186/1465-9921-13-117
6. Corradi et al. Aldehydes in Exhaled Breath Condensate of Patients with Chronic Obstructive Pulmonary Disease, Am J Respir Crit Care Med. 2002, DOI: 10.1164/rccm.200210-1253OC
7. Mazzone, Analysis of Volatile Organic Compounds in the Exhaled Breath for the Diagnosis of Lung Cancer, J Thoracic Onc. 2008, DOI: 10.1097/JTO.0b013e31817c7439
8. Poli et al. Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME–GC/MS, J Chromat B. 2010, DOI: 10.1016/j.jchromb.2010.01.022
9. Liu, Li and Duan, Effect of H2O2 induced oxidative stress (OS) on volatile organic compounds (VOCs) and intracellular metabolism in MCF-7 breast cancer cells, J Breath Res. 2019, DOI: 10.1088/1752-7163/ab14a5
10. Hietanen et al. Diet and oxidative stress in breast, colon and prostate cancer patients: a case-control study, Eur J Clin Nutr, 1994. https://pubmed.ncbi.nlm.nih.gov/7957003/ 
11. Furuhashi et al. Elucidation of Biochemical Pathways Underlying VOCs Production in A549 Cells, Front Mol Biosci. 2020, DOI: 10.3389/fmolb.2020.00116
12. Hanouneh et al. The Breathprints in Patients With Liver Disease Identify Novel Breath Biomarkers in Alcoholic Hepatitis, Clin Gastrol Hepatol. 2014, DOI: 10.1016/j.cgh.2013.08.048
13. Duchatelle et al. Increased ethane exhalation, an in vivo index of lipid peroxidation, in alcohol-abusers, Gut. 1993, DOI: 10.1136/gut.34.3.409
14. Sobotka et al. Breath pentane is a marker of acute cardiac allograft rejection. J Heart Lung Transplant, 1994 https://pubmed.ncbi.nlm.nih.gov/8031804/ 
15. Phillips et al. Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study). J Heart Lung Transplant, 2004, DOI: 10.1016/j.healun.2003.07.017
16. Gaude et al. Targeted breath analysis: exogenous volatile organic compounds (EVOC) as metabolic pathway-specific probes. J Breath Res. 2019, DOI: 10.1088/1752-7163/ab1789
17. Lamote et al. Exhaled breath to screen for malignant pleural mesothelioma: a validation study. Eur Respir J. 2017, DOI: 10.1183/13993003.00919-2017
18. Phillips et al. Breath markers of oxidative stress in patients with unstable angina. Heart Dis. 2003, DOI: 10.1097/01.hdx.0000061701.99611.e8
19. Pelli et al. Breath alkanes determination in ulcerative colitis and Crohn's disease. Dis Colon Rect. 1999, DOI: 10.1007/BF02235186
20. Sedghi et al. Elevated breath ethane levels in active ulcerative colitis: evidence for excessive lipid peroxidation. Am J Gastroenterol. 1994 https://pubmed.ncbi.nlm.nih.gov/7977245/